The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to severe acute pain in adults. The drug is manufactured by Vertex Pharmaceuticals. According to the FDA, Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain. 

Related News Articles

Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Perspective
Public
The 2025 AHA Leadership Summit wrapped up on July 22, and as always, it was energizing and inspiring to connect with so many talented and dedicated people…
Perspective
Public
Personalized cancer vaccines that are tailored to individual patients, targeting the specific mutations present in their tumors.AI analysis of pathology slides…
Headline
The Centers for Medicare & Medicaid Services June 27 announced the rollout of a 6-year technology-enabled prior authorization program pilot. Through…
Headline
The AHA today launched the new Care Delivery Transformation Framework that aims to support hospitals and health systems with tools and resources for the…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…